Form 6-K Summary
Registrant: NLS Pharmaceutics Ltd. (the provided metadata identifies Newcelx Ltd.; the filing itself names NLS Pharmaceutics Ltd.)
Reporting period: October 2022, Report No. 3. Filed October 7, 2022, under Commission file number 001-39957.
Business Context and Corporate Actions
On October 4, 2022, NLS Pharmaceutics filed amended and restated Articles of Association with the commercial registry of the Canton of Zurich, Switzerland. The filing reflects changes to outstanding share capital and authorized and conditional share capital.
Capital Structure
- Outstanding share capital increased to CHF 533,635.34, divided into 26,681,767 registered shares.
- Authorized share capital permits issuance of up to CHF 69,156.88, representing up to 3,457,844 registered shares, through May 31, 2024.
- Conditional share capital for employee and adviser options totals up to CHF 42,182, representing up to 2,109,100 registered shares.
- New conditional share capital for shareholder options totals up to CHF 137,606.26, representing up to 6,880,313 registered shares.
Financial Performance and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-financial metrics. It also does not present a comparable prior-period financial analysis.
Guidance, Risks, and Unusual Items
No guidance or operating outlook is provided. The principal disclosed development is the amended capital structure, which could permit future share issuances and potentially result in dilution. The amended Articles are filed as Exhibit 3.1.
The report is incorporated by reference into the company’s Form F-3 registration statement, File No. 333-262489, to the extent not superseded by later filings.
Investor Verification Points
- Verify the registrant identity, because the supplied metadata names Newcelx Ltd., while the filing names NLS Pharmaceutics Ltd.
- Review Exhibit 3.1 for the complete amended and restated Articles of Association.
- Assess the potential dilution associated with the authorized and conditional share capital limits.
- Check subsequent SEC filings for any issuance of shares or exercise of employee, adviser, or shareholder options.
- Consult the company’s periodic reports for financial performance, liquidity, debt, and operating outlook, none of which are provided in this Form 6-K.